Assistant Professor, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health
Dr. Carla R. Nowosad is an Assistant Professor in the Department of Pathology and the Translational Immunology Center at NYU Grossman School of Medicine, where she established her laboratory in 2021. She received undergraduate degrees from the University of Warwick and her PhD from the Francis Crick Institute, National Institute for Medical Research Mill Hill, University College London. She completed postdoctoral training at The Rockefeller University in the laboratories of Gabriel Victora and Daniel Mucida.
Dr. Nowosad’s research focuses on how B cells make decisions in the complex microenvironment of the intestine. Her work investigates the dynamics of germinal center B cell selection in gut-associated lymphoid tissue, the interplay between B cells and the intestinal microbiome, and how these interactions shape antibody responses in health and disease. Her landmark 2020 paper in Nature demonstrated that B cell selection in gut germinal centers operates through tunable dynamics distinct from those in other lymphoid tissues — a finding with important implications for understanding mucosal immunity and autoimmune disease.
Dr. Nowosad’s work has been recognized by the V Foundation for Cancer Research, and she has published in leading journals including Nature, Nature Immunology, and Science.
Carla R. Nowosad, PhD
Colton Consortium Member
Areas of Focus:
Adaptive ImmunityAnimal ModelsB Cell BiologyBiological & MechanisticData-Driven & QuantitativeExperimental Platforms & ModelsImmune ToleranceIn Vitro ModelsMicrobiome–Immune InteractionsMulti-omics IntegrationSingle Cell TechnologiesSpatial BiologyGastrointestinal Diseases
Projects
Featured Pilot Projects

Project | New York University
Spatial Dynamics of Intestinal B Cell Immunoreceptor Signaling in Health and Disease (IBD)
Using single-molecule imaging to visualize B cell receptor signaling across gut compartments, this project uncovers how intestinal B cell education breaks down in IBD, revealing new targets for therapeutic intervention.